The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Genomic characterization of non-progressor smoldering multiple myeloma
Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, outlines the findings of a study investigating the genomic and transcriptomic features of patients with smoldering multiple myeloma who do not progress to multiple myeloma. Using whole-genome and transcriptome profiling in patients with smoldering multiple myeloma who had and had not progressed to multiple myeloma after a five-year follow-up, the study identified three characteristics of non-progressor smoldering multiple myeloma: a low mutational load, an absence of chromosome 8 copy number change, and a low deletion count. In addition, transcriptomic analysis highlighted that expression of MYC target genes and DNA repair pathway genes in non-progressor smoldering multiple myeloma cells was similar to normal plasma cells. Together with the recently defined genomic features of high-risk smoldering multiple myeloma, this genomic characterization will help select the right patient subgroups for clinical trials and provide assurance to patients with non-progressor smoldering multiple myeloma. It is important to validate these findings in a larger dataset. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
